Join our executive leaders and subject matter experts from the 340B Prime Vendor Program, managed by Apexus, at these educational and operational sessions:
Sunday, May 19
8:00 a.m.–4:45 p.m.
340B University is an educational program designed to meet the practical needs of 340B Program participants and other program stakeholders. Participants learn from 340B subject matter experts, experienced faculty and networking with peers. Continuing education credit is available for pharmacists and pharmacy technicians. There is no fee to attend this training. Breakfast and box lunch are provided.
Monday, May 20
8:45–9:15 a.m.
Join us for our official welcome, level-setting the environment of CEs and the 340B Drug Pricing Program, as well as hear from our Presenting Sponsors.
Speaker
Chris Hatwig, MS, RPh, FASHP
President
Apexus
Monday, May 20
11:15 a.m.–12:30 p.m.
This session will dive into 340B issues unique to CHCs, including OPAIS registration, BPHC operational site visits, and the sliding fee discount program. Speakers will also provide analysis on the Inflation Reduction Act, its anticipated impact on the Medicaid and Medicare programs, and how that intersects with 340B.
Speaker
Jangus Whitner, PharmD, MHA, BCACP, 340B ACE
340B Policy and Compliance Director
Apexus
Monday, May 20
3:00–4:15 p.m.
General overview and importance of 340B as a financial driver to support program development at your organization. Topics will include experiences investing savings across in-house development of dispensing pharmacies, clinical programs, and services. Program creation and overview from an administrative, senior leadership perspective, showing the relationship of 340B to program development and investment.
Speaker
Michelle Fox, MBA, CGMS, 340B ACE
340B Policy and Compliance Director
Apexus
Tuesday, May 21
11:15 a.m.–12:30 p.m.
This session will demonstrate how using data derived from the 340B Program can improve the continuum of care and close gaps in care that result in improved health plan metrics and patient outcomes.
Speaker
Shelly Dusing Wiest, PharmD, BCPS, FASHP, 340B ACE
Senior Vice President, 340B Policy and Compliance
Apexus
Tuesday, May 21
3:00–4:15 p.m.
This session will review the pivotal role the Prime Vendor Program plays in the utilization of clinic-administered drugs. Clinic-administered drugs are audited by HRSA to ensure transparent and ethical practices, but the process is slightly different from contract pharmacy audits. Attendees of this presentation will gain valuable insights into HRSA’s audit procedures for clinic-administered drugs. Join us to gain the expertise to apply tools and resources from the Prime Vendor Program to navigate HRSA audits, ensuring transparent and compliant utilization of clinic-administered drugs.
Speaker
Michelle Fox, MBA, CGMS, 340B ACE
340B Policy and Compliance Director
Apexus
Tuesday, May 21
3:00–4:15 p.m.
This discussion-based session, designed for C-suite and board members, focuses on strategically integrating the 340B Drug Pricing Program. Learn to incorporate 340B into your organization's strategic vision and draft an actionable strategic statement. Engage in discussions emphasizing grantee leadership's role in ensuring compliance and maximizing 340B benefits, culminating in a reflective segment highlighting two key leadership responsibilities.
Speaker
Chris Hatwig, MS, RPh, FASHP
President
Apexus
Quickly select your next educational experience by keyword or subject, stakeholder group, and level of 340B knowledge from basic to more advanced topics. Easily choose among in-person events, online courses, and virtual events.
Build your own training plan or create a roadmap to fulfill employer annual 340B training requirements. Personalize your path to advance your 340B knowledge.
Access Buyer Basics courses to understand how the 340B Program affects drug purchasing. Use the buyer role education roadmap to see all the PVP tools available for buyers.
Frequently asked questions (FAQs) provided by HRSA to address common 340B Program compliance questions.
Search Medicaid 340B requirements by state.
Select your communication preferences.
The most common reason is that your organization’s email system is blocking messages from us. Follow these whitelist instructions.